KRAS and neoplasm: Using the TST vendor-supplied bioinformatics pipeline we were able to detect and validate by orthogonal methods known activating driver mutations in EGFR, KRAS and BRAF below 5% VAF in cases with ≥10% tumor cell content by routine pathological assessment.